Tasly Pharmaceutical Group Company Limited operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Tasly Pharmaceutical Group Company Limited with three other
companies in this sector in CHINA :
Sichuan Kelun Pharmaceutical Company Limited
sales of 17.64 billion Chinese Renmimbi [US$2.68 billion]
of which 98%
was Medical and Pharmaceutical Products),
Jiangsu Hengrui Medicine Co Ltd
(23.29 billion Chinese Renmimbi [US$3.54 billion]
of which 100%
was Medicinal Manufacturing), and
Humanwell Healthcare Group Co Ltd
(21.81 billion Chinese Renmimbi [US$3.32 billion]
of which 90%
was Medication & Health Products).
Tasly Pharmaceutical Group Company Limited reported sales of 19.00 billion Chinese Renmimbi (US$2.89 billion)
December of 2019.
increase of 5.6%
versus 2018, when the company's sales were 17.99 billion Chinese Renmimbi.
Sales at Tasly Pharmaceutical Group Company Limited have increased during each of the previous five years
(and since 2014, sales have increased a total of 51%).
Sales of Medicine Commerce saw an increase
that was more than double the company's growth rate: sales were up
18.0% in 2019, from
10.78 billion Chinese Renmimbi to 12.72 billion Chinese Renmimbi.
Not all segments of Tasly Pharmaceutical Group Company Limited experienced an increase in sales in 2019:
sales of Other fell 22.1% to 65.83 million Chinese Renmimbi.
(However, this segment's sales were only a very small portion of the company's overall sales).
Tasly Pharmaceutical Group Company Limited also experienced decreases in sales in
Pharmaceutical and Medicine Manufacturing (down 12.8% to 6.22 billion Chinese Renmimbi)